University of Lyon, F-69000 Lyon, France.
Biomark Med. 2013 Aug;7(4):663-71. doi: 10.2217/bmm.13.48.
Gemcitabine is a nucleoside analog that is indicated in the treatment of pancreatic cancer. In order to provide a better use of this drug, the search for immunohistological markers is a hot topic in the field of pancreatic cancer. In particular, the use of nucleoside transporter hENT1 and the intracellular target of gemcitabine RRM1 are current subjects for discussion. We have analyzed the majority of studies of hENT1 and RRM1 on pancreatic cancer, and will discuss the further directions that might be followed in order to integrate these proteins in routine clinical practice. The data that is currently available would benefit from the completion of well-designed randomized trials in order to confirm the clinical value of hENT1 and RRM1 as biomarkers in pancreatic cancer patients.
吉西他滨是一种核苷类似物，适用于胰腺癌的治疗。为了更好地使用这种药物，寻找免疫组织化学标志物是胰腺癌领域的一个热门话题。特别是核苷转运蛋白 hENT1 和吉西他滨的细胞内靶点 RRM1 的使用，是当前讨论的主题。我们分析了大多数关于胰腺癌的 hENT1 和 RRM1 的研究，并将讨论为了将这些蛋白质纳入常规临床实践中可能遵循的进一步方向。目前可用的数据将受益于精心设计的随机试验的完成，以确认 hENT1 和 RRM1 作为胰腺癌患者生物标志物的临床价值。
